IGF-I Antibody (W18): sc-74116

IGF-I Antibody (W18) is a mouse monoclonal IgG1 kappa light chain antibody that detects IGF-I of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). IGF-I (W18) antibody is available in a non-conjugated form, providing flexibility for various experimental needs. Insulin-like growth factor I (IGF-I) is a critical peptide hormone that plays a vital role in growth and development, acting in both autocrine and paracrine manners to stimulate vascular smooth muscle cell proliferation. IGF-I is primarily located in the bloodstream and produced mainly by the liver in response to growth hormone stimulation. This localization allows IGF-I to exert systemic effects on tissues throughout the body, influencing processes such as cell growth, differentiation, and metabolism. IGF-I is essential for normal bone growth and repair, as well as for regulation of renal function and immune response. IGF-I biological activity is modulated by a family of six IGF-binding proteins (IGFBP1-6), which can either enhance or inhibit actions, thereby fine-tuning effects on various physiological processes. Understanding IGF-I dynamics and interactions is crucial for elucidating roles in health and disease, particularly in conditions related to growth disorders and metabolic syndromes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IGF-I Antibody (W18) References:

1. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.  |  Sachdev, D., et al. 2003. Cancer Res. 63: 627-35. PMID: 12566306
2. The IGF-I/IGF-R1 pathway regulates postnatal lung growth and is a nonspecific regulator of alveologenesis in the neonatal rat.  |  Li, J., et al. 2013. Am J Physiol Lung Cell Mol Physiol. 304: L626-37. PMID: 23457189
3. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.  |  Ma, CX., et al. 2013. Breast Cancer Res Treat. 139: 145-53. PMID: 23605083
4. Effects of growth hormone and insulin-like growth factor I on the immune system.  |  Auernhammer, CJ. and Strasburger, CJ. 1995. Eur J Endocrinol. 133: 635-45. PMID: 8548046
5. Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor.  |  Jiang, Y., et al. 1996. J Biol Chem. 271: 160-7. PMID: 8550552
6. Hepatic overexpression of insulin-like growth factor-II in adulthood increases basal and insulin-stimulated glucose disposal in conscious mice.  |  Rossetti, L., et al. 1996. J Biol Chem. 271: 203-8. PMID: 8550560
7. G-protein coupled and tyrosine kinase receptors: evidence that activation of the insulin-like growth factor I receptor is required for thrombin-induced mitogenesis of rat aortic smooth muscle cells.  |  Delafontaine, P., et al. 1996. J Clin Invest. 97: 139-45. PMID: 8550825
8. Insulin-like growth factor binding protein-1 inhibits arterial smooth muscle cell proliferation in vitro but does not reduce the neointimal response to balloon catheter injury.  |  Motani, A., et al. 1995. Atherosclerosis. 118: 57-66. PMID: 8579632
9. The insulin-like growth factor system and the coupling of formation to resorption.  |  Hayden, JM., et al. 1995. Bone. 17: 93S-98S. PMID: 8579905
10. Expression of the genes encoding the rat renal insulin-like growth factor-I system.  |  Rabkin, R., et al. 1995. J Am Soc Nephrol. 6: 1511-8. PMID: 8589331
11. Further characterisation of an IGF-I enhancing antibody: actions on IGF-I-induced hypoglycaemia and interaction with the analogue LR3IGF-I.  |  Pell, JM., et al. 1995. Prog Growth Factor Res. 6: 367-75. PMID: 8817680
12. Regulation of insulin-like growth factor I (IGF-I) bioactivity in vivo: further characterization of an IGF-I-enhancing antibody.  |  Hill, RA. and Pell, JM. 1998. Endocrinology. 139: 1278-87. PMID: 9492063

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-IGF-I Antibody (W18) has 23 citations in a variety of scientific publications.

Primary antibodies like Anti-IGF-I Antibody (W18) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

IGF-I Antibody (W18) Specifications

Alternate Product Name: IGF-1

Product Clone Name: W18

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 49-118

Epitope Target: IGF-I

Epitope Species: human

Product Reactivity/Detection: IGF-I

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 50 µg IgG₁ kappa light chain in 0.5 ml of PBS with < 0.1% sodium azide and protein stabilizer

Research Citations: 23 citations in various scientific publications

Available Conjugates/Forms for IGF-I Antibody (W18): N/A